Avilash Mondal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avilash Mondal has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Rupak Desai
Atlanta VA Medical Center, Decatur, GA
7 shared publications Amro Taha
2 shared publications- Aobo Li
Inspira Medical Center
2 shared publications - Sashwath Srikanth
East Carolina University, USA
2 shared publications - Sittinun Thangjui
West Virginia University
2 shared publications - Sudarshan Balla
Department of Cardiology, West Virginia University, Morgantown, Wv, USA
2 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (30)
Takotsubo Cardiomyopathy With Dynamic LVOT Obstruction Mimicking Inferior STEMI
- 29 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (30)
Open AccessTakotsubo Cardiomyopathy With Dynamic LVOT Obstruction Mimicking Inferior STEMI
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e045998
Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy
Background: Patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal trials comparing the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists. Methods: Our retrospective cohort study using the TriNetX database compared adults with HCM‐atrial fibrillation who initiated DOACs or vitamin K antagonists. The primary outcomes were all‐cause mortality and ischemic stroke/systemic thromboembolism. Secondary outcomes included major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause hospitalization. Subgroup analysis was conducted for obstructive HCM. Results: Among 13 143 patients with HCM‐atrial fibrillation (2963 matched pairs). DOAC use was associated with lower all‐cause mortality (hazard ratio [HR], 0.82[ 95% CI, 0.73–0.93]; P P =0.03), and intracranial hemorrhage (HR, 0.54 [95% CI, 0.36–0.79]; P =0.001) compared with vitamin K antagonists. No differences were observed in the rates of ischemic stroke (HR, 0.94 [95% CI, 0.73–1.2]; P =0.6) or the composite of stroke or systemic thromboembolism (HR, 0.87 [95% CI, 0.69–1.10]; P =0.25), gastrointestinal bleeding (HR, 0.97 [95% CI, 0.77–1.22]; P =0.82), or all‐cause hospitalizations (HR, 1.07 [95% CI, 0.93–1.07]; P =0.051). In the subgroup with obstructive HCM, DOAC use was associated with a reduced risk of all‐cause mortality (HR, 0.80 [95% CI, 0.66–0.99]; P =0.035) and major bleeding (HR, 0.76 [95% CI, 0.61–0.96]; P =0.02) without stroke or thromboembolic risk reduction (HR, 0.69 [95% CI, 0.47–1.01]; P =0.05). Conclusions: Among patients with HCM‐atrial fibrillation, DOACs were associated with lower mortality and bleeding risk compared with vitamin K antagonists, with no increased risk of stroke or systemic thromboembolism.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e045998
Open AccessEfficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy
Background: Patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal trials comparing the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists. Methods: Our retrospective cohort study using the TriNetX database compared adults with HCM‐atrial fibrillation who initiated DOACs or vitamin K antagonists. The primary outcomes were all‐cause mortality and ischemic stroke/systemic thromboembolism. Secondary outcomes included major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause hospitalization. Subgroup analysis was conducted for obstructive HCM. Results: Among 13 143 patients with HCM‐atrial fibrillation (2963 matched pairs). DOAC use was associated with lower all‐cause mortality (hazard ratio [HR], 0.82[ 95% CI, 0.73–0.93]; P P =0.03), and intracranial hemorrhage (HR, 0.54 [95% CI, 0.36–0.79]; P =0.001) compared with vitamin K antagonists. No differences were observed in the rates of ischemic stroke (HR, 0.94 [95% CI, 0.73–1.2]; P =0.6) or the composite of stroke or systemic thromboembolism (HR, 0.87 [95% CI, 0.69–1.10]; P =0.25), gastrointestinal bleeding (HR, 0.97 [95% CI, 0.77–1.22]; P =0.82), or all‐cause hospitalizations (HR, 1.07 [95% CI, 0.93–1.07]; P =0.051). In the subgroup with obstructive HCM, DOAC use was associated with a reduced risk of all‐cause mortality (HR, 0.80 [95% CI, 0.66–0.99]; P =0.035) and major bleeding (HR, 0.76 [95% CI, 0.61–0.96]; P =0.02) without stroke or thromboembolic risk reduction (HR, 0.69 [95% CI, 0.47–1.01]; P =0.05). Conclusions: Among patients with HCM‐atrial fibrillation, DOACs were associated with lower mortality and bleeding risk compared with vitamin K antagonists, with no increased risk of stroke or systemic thromboembolism.
- Open Access
Predictors of Secondary Pulmonary Hypertension-Related Hospitalizations and Subsequent Mortality in Adults with Obstructive Sleep Apnea
Background: Secondary pulmonary hypertension (SPH) predicts poor outcomes in obstructive sleep apnea (OSA) patients. This study examines sex/racial disparities, predictors, and inpatient mortality in SPH-related OSA hospitalizations. Methods: We used the National Inpatient Sample (2019) and ICD-10 codes to identify OSA-related hospitalizations with SPH. The burden of SPH and disparities by sex/race were assessed. We also compared the odds and predictors of in-hospital mortality in OSA patients with vs. without SPH. Results: Of total adult OSA hospitalizations (n = 2,317,136, median age of 66 [56–74] years, and males: 57.2%), 9.4% (218,795/2,317,136) had SPH. Females vs. males (11.3% vs. 8.1%) and Blacks vs. other race groups (13.5%) with OSA had a higher prevalence of SPH. The SPH cohort often consisted of females (51 vs. 41.9%), Blacks (20.9 vs. 14.0%), Medicare-insured (73.4 vs. 60.6%), and non-elective admissions (89.2 vs. 74.4%) vs. the non-SPH cohort. The SPH cohort also had a higher burden of complicated HTN (52.9 vs. 36.3%), DM with complications (42.7 vs. 32.4%), COPD (52.5 vs. 36.9%), history of prior MI (11.4 vs. 9.6%), and venous thromboembolism (10.4 vs. 8.4%). However, in-hospital mortality was more likely to be in males (OR 1.12; 95%CI 1.00–1.25, p = 0.048) vs. females, and OSA patients with metastatic cancer (OR 2.73; 95%CI 2.04–3.65) and solid non-metastatic tumors (OR 1.65; 95%CI 1.26–2.15) (p < 0.001). Conclusions: The prevalence of SPH with OSA was greater in females and Blacks, whereas males and Whites had higher subsequent inpatient mortality. More prospective studies are needed to understand the role of comorbidities on survival outcomes.
Open AccessPredictors of Secondary Pulmonary Hypertension-Related Hospitalizations and Subsequent Mortality in Adults with Obstructive Sleep Apnea
Background: Secondary pulmonary hypertension (SPH) predicts poor outcomes in obstructive sleep apnea (OSA) patients. This study examines sex/racial disparities, predictors, and inpatient mortality in SPH-related OSA hospitalizations. Methods: We used the National Inpatient Sample (2019) and ICD-10 codes to identify OSA-related hospitalizations with SPH. The burden of SPH and disparities by sex/race were assessed. We also compared the odds and predictors of in-hospital mortality in OSA patients with vs. without SPH. Results: Of total adult OSA hospitalizations (n = 2,317,136, median age of 66 [56–74] years, and males: 57.2%), 9.4% (218,795/2,317,136) had SPH. Females vs. males (11.3% vs. 8.1%) and Blacks vs. other race groups (13.5%) with OSA had a higher prevalence of SPH. The SPH cohort often consisted of females (51 vs. 41.9%), Blacks (20.9 vs. 14.0%), Medicare-insured (73.4 vs. 60.6%), and non-elective admissions (89.2 vs. 74.4%) vs. the non-SPH cohort. The SPH cohort also had a higher burden of complicated HTN (52.9 vs. 36.3%), DM with complications (42.7 vs. 32.4%), COPD (52.5 vs. 36.9%), history of prior MI (11.4 vs. 9.6%), and venous thromboembolism (10.4 vs. 8.4%). However, in-hospital mortality was more likely to be in males (OR 1.12; 95%CI 1.00–1.25, p = 0.048) vs. females, and OSA patients with metastatic cancer (OR 2.73; 95%CI 2.04–3.65) and solid non-metastatic tumors (OR 1.65; 95%CI 1.26–2.15) (p < 0.001). Conclusions: The prevalence of SPH with OSA was greater in females and Blacks, whereas males and Whites had higher subsequent inpatient mortality. More prospective studies are needed to understand the role of comorbidities on survival outcomes.
- Open Access
- 11 January 2025
- Published by Elsevier in Obesity Pillars
- Vol. 13, 100158
Cardiovascular outcomes in metabolically healthy Asian-American population with obesity (18–44 years): Insights from the National Inpatient Sample
- 11 January 2025
- Published by Elsevier in Obesity Pillars
- Vol. 13, 100158
Open AccessCardiovascular outcomes in metabolically healthy Asian-American population with obesity (18–44 years): Insights from the National Inpatient Sample
- 23 July 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (10) , 563-569
Impact of right ventricular failure on the outcomes of acute inferior wall myocardial infarction
Aim: Right ventricular failure (RVF) complicates 30-50% of cases with inferior wall myocardial infarctions (IWMI). Large-scale studies exploring the recent trends in morbidity and mortality of IWMI with RVF in the context of improved reperfusion strategies are currently lacking. Materials & methods: The International Classification of Diseases, Tenth Revision, Clinical Modification codes were used to query the National Inpatient Sample of 2018-2019 to yield IWMI admissions and stratified based on presence of RVF. The primary outcome was in-hospital mortality. Results: Out of the 182,485 weighed hospital admissions for IWMI, 1005 patients (0.6%) also had RVF. Patients with both IWMI and RVF had significantly higher mortality than patients with IWMI and no RVF (p < 0.001). Conclusion: RVF in patients with IWMI is an independent predictor of poor outcomes.
- 23 July 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (10) , 563-569
Impact of right ventricular failure on the outcomes of acute inferior wall myocardial infarction
Aim: Right ventricular failure (RVF) complicates 30-50% of cases with inferior wall myocardial infarctions (IWMI). Large-scale studies exploring the recent trends in morbidity and mortality of IWMI with RVF in the context of improved reperfusion strategies are currently lacking. Materials & methods: The International Classification of Diseases, Tenth Revision, Clinical Modification codes were used to query the National Inpatient Sample of 2018-2019 to yield IWMI admissions and stratified based on presence of RVF. The primary outcome was in-hospital mortality. Results: Out of the 182,485 weighed hospital admissions for IWMI, 1005 patients (0.6%) also had RVF. Patients with both IWMI and RVF had significantly higher mortality than patients with IWMI and no RVF (p < 0.001). Conclusion: RVF in patients with IWMI is an independent predictor of poor outcomes.
- Open Access
- 25 May 2024
- Published by Elsevier in Obesity Pillars
- Vol. 11, 100114
In-hospital outcomes in metabolically healthy and unhealthy individuals over 65 years of age with obesity undergoing percutaneous intervention for acute coronary syndrome: A nationwide propensity-matched analysis (2016–2020)
- 25 May 2024
- Published by Elsevier in Obesity Pillars
- Vol. 11, 100114
Open AccessIn-hospital outcomes in metabolically healthy and unhealthy individuals over 65 years of age with obesity undergoing percutaneous intervention for acute coronary syndrome: A nationwide propensity-matched analysis (2016–2020)
- Open Access
- 26 March 2024
- Published by MDPI AG in Preprints.org
Pivotal Role of Artificial Intelligence in Cardiovascular Health: Highlights from the Late Breaking Trials at the AHA Scientific Sessions 2023
Cardiovascular diseases (CVDs) remain the leading cause of mortality. Traditional approaches to diagnosing and treating CVDs often involve interpretation, which can lead to errors. The emergence of Artificial Intelligence (AI) and Machine Learning aids the management of CVDs. AI examines amounts of data and identifies patterns offering solutions for disease detection, risk prediction, and patient care. The American Heart Association's 2023 Scientific Sessions (AHA23) showcased studies that highlight AIs potential to revolutionize cardiac healthcare. This article presents a review of these cutting-edge studies exploring how AI is applied in health, the outcomes of these applications, and their implications for clinical practice. The insights gained from this review will contribute to the discussion on AI's role in healthcare and its capacity to enhance outcomes.
- 26 March 2024
- Published by MDPI AG in Preprints.org
Open AccessPivotal Role of Artificial Intelligence in Cardiovascular Health: Highlights from the Late Breaking Trials at the AHA Scientific Sessions 2023
Cardiovascular diseases (CVDs) remain the leading cause of mortality. Traditional approaches to diagnosing and treating CVDs often involve interpretation, which can lead to errors. The emergence of Artificial Intelligence (AI) and Machine Learning aids the management of CVDs. AI examines amounts of data and identifies patterns offering solutions for disease detection, risk prediction, and patient care. The American Heart Association's 2023 Scientific Sessions (AHA23) showcased studies that highlight AIs potential to revolutionize cardiac healthcare. This article presents a review of these cutting-edge studies exploring how AI is applied in health, the outcomes of these applications, and their implications for clinical practice. The insights gained from this review will contribute to the discussion on AI's role in healthcare and its capacity to enhance outcomes.
- Open Access
- 19 February 2024
- Published by MDPI AG in Medical Sciences
- Vol. 12 (1) , 13
Association of Cannabis Use Disorder with Major Adverse Cardiac and Cerebrovascular Events in Older Non-Tobacco Users: A Population-Based Analysis
Background: Tobacco use disorder (TUD) adversely impacts older patients with established cardiovascular disease (CVD) risk. However, CVD risk in chronic habitual cannabis users without the confounding impact of TUD hasn’t been explored. We aimed to determine the risk of major adverse cardiac and cerebrovascular events (MACCE) in older non-tobacco smokers with established CVD risk with vs. without cannabis use disorder (CUD). Methods: We queried the 2019 National Inpatient Sample for hospitalized non-tobacco smokers with established traditional CVD risk factors aged ≥65 years. Relevant ICD-10 codes were used to identify patients with vs. without CUD. Using multivariable logistic regression, we evaluated the odds of MACCE in CUD cohorts compared to non-CUD cohorts. Results: Prevalence of CUD in the sample was 0.3% (28,535/10,708,815, median age 69), predominantly male, black, and non-electively admitted from urban teaching hospitals. Of the older patients with CVD risk with CUD, 13.9% reported MACCE. The CUD cohort reported higher odds of MACCE (OR 1.20, 95% CI 1.11–1.29, p < 0.001) compared to the non-CUD cohort. Comorbidities such as hypertension (OR 1.9) and hyperlipidemia (OR 1.3) predicted a higher risk of MACCE in the CUD cohort. The CUD cohort also had higher unadjusted rates of acute myocardial infarction (7.6% vs. 6%) and stroke (5.2% vs. 4.8%). Conclusions: Among older non tobacco smokers with known CVD risk, chronic cannabis use had a 20% higher likelihood of MACCE compared to those who did not use cannabis.
- 19 February 2024
- Published by MDPI AG in Medical Sciences
- Vol. 12 (1) , 13
Open AccessAssociation of Cannabis Use Disorder with Major Adverse Cardiac and Cerebrovascular Events in Older Non-Tobacco Users: A Population-Based Analysis
Background: Tobacco use disorder (TUD) adversely impacts older patients with established cardiovascular disease (CVD) risk. However, CVD risk in chronic habitual cannabis users without the confounding impact of TUD hasn’t been explored. We aimed to determine the risk of major adverse cardiac and cerebrovascular events (MACCE) in older non-tobacco smokers with established CVD risk with vs. without cannabis use disorder (CUD). Methods: We queried the 2019 National Inpatient Sample for hospitalized non-tobacco smokers with established traditional CVD risk factors aged ≥65 years. Relevant ICD-10 codes were used to identify patients with vs. without CUD. Using multivariable logistic regression, we evaluated the odds of MACCE in CUD cohorts compared to non-CUD cohorts. Results: Prevalence of CUD in the sample was 0.3% (28,535/10,708,815, median age 69), predominantly male, black, and non-electively admitted from urban teaching hospitals. Of the older patients with CVD risk with CUD, 13.9% reported MACCE. The CUD cohort reported higher odds of MACCE (OR 1.20, 95% CI 1.11–1.29, p < 0.001) compared to the non-CUD cohort. Comorbidities such as hypertension (OR 1.9) and hyperlipidemia (OR 1.3) predicted a higher risk of MACCE in the CUD cohort. The CUD cohort also had higher unadjusted rates of acute myocardial infarction (7.6% vs. 6%) and stroke (5.2% vs. 4.8%). Conclusions: Among older non tobacco smokers with known CVD risk, chronic cannabis use had a 20% higher likelihood of MACCE compared to those who did not use cannabis.
- Open Access
- 19 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 573
Association of Prediabetes and Recurrent Stroke in Atrial Fibrillation Patients: A Population-Based Analysis of Hospitalizations and Outcomes
Prediabetes is a risk factor for ischemic stroke in atrial fibrillation (AF) patients, yet, its impact on recurrent stroke in AF patients remains understudied. Using the 2018 National Inpatient Sample, we investigated the link between Prediabetes and recurrent stroke in AF patients with prior stroke or transient ischemic attack (TIA). Among 18,905 non-diabetic AF patients, 480 (2.5%) had prediabetes. The prediabetic group, with a median age of 78, exhibited a two-fold higher risk of recurrent stroke compared to the non-prediabetic cohort (median age 82), as evidenced by both unadjusted (OR 2.14, 95% CI 1.72–2.66) and adjusted (adjusted for socio-demographics/comorbidities, OR 2.09, 95% CI 1.65–2.64, p < 0.001). The prediabetes cohort, comprising more male and Black patients, demonstrated associations with higher Medicaid enrollment, admissions from certain regions, and higher rates of hyperlipidemia, smoking, peripheral vascular disease, obesity, and chronic obstructive pulmonary disease (all p < 0.05). Despite higher rates of home health care and increased hospital costs in the prediabetes group, the adjusted odds of all-cause mortality were not statistically significant (OR 0.55, 95% CI 0.19–1.56, p = 0.260). The findings of this study suggest that clinicians should be vigilant in managing prediabetes in AF patients, and strategies to prevent recurrent stroke in this high-risk population should be considered.
- 19 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 573
Open AccessAssociation of Prediabetes and Recurrent Stroke in Atrial Fibrillation Patients: A Population-Based Analysis of Hospitalizations and Outcomes
Prediabetes is a risk factor for ischemic stroke in atrial fibrillation (AF) patients, yet, its impact on recurrent stroke in AF patients remains understudied. Using the 2018 National Inpatient Sample, we investigated the link between Prediabetes and recurrent stroke in AF patients with prior stroke or transient ischemic attack (TIA). Among 18,905 non-diabetic AF patients, 480 (2.5%) had prediabetes. The prediabetic group, with a median age of 78, exhibited a two-fold higher risk of recurrent stroke compared to the non-prediabetic cohort (median age 82), as evidenced by both unadjusted (OR 2.14, 95% CI 1.72–2.66) and adjusted (adjusted for socio-demographics/comorbidities, OR 2.09, 95% CI 1.65–2.64, p < 0.001). The prediabetes cohort, comprising more male and Black patients, demonstrated associations with higher Medicaid enrollment, admissions from certain regions, and higher rates of hyperlipidemia, smoking, peripheral vascular disease, obesity, and chronic obstructive pulmonary disease (all p < 0.05). Despite higher rates of home health care and increased hospital costs in the prediabetes group, the adjusted odds of all-cause mortality were not statistically significant (OR 0.55, 95% CI 0.19–1.56, p = 0.260). The findings of this study suggest that clinicians should be vigilant in managing prediabetes in AF patients, and strategies to prevent recurrent stroke in this high-risk population should be considered.
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100695
A-31 | Major Adverse Cardiovascular Events in Patients Developing New-Onset Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100695
Open AccessA-31 | Major Adverse Cardiovascular Events in Patients Developing New-Onset Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.